NASDAQ:SLRX - Salarius Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 290.63 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.28
▼ -0.07 (-5.19%)
1 month | 3 months | 12 months
Get New Salarius Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +290.63% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Salarius Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 290.63% upside from the last price of $1.28.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Salarius Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/16/2020BenchmarkInitiated CoverageBuy$5.00Medium
i
4/27/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
i
(Data available from 3/6/2016 forward)
Salarius Pharmaceuticals logo
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Read More

Today's Range

Now: $1.28
$1.17
$1.40

50 Day Range

MA: $1.76
$1.09
$3.00

52 Week Range

Now: $1.28
$0.56
$3.50

Volume

2,645,470 shs

Average Volume

3,553,438 shs

Market Capitalization

$30.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Salarius Pharmaceuticals?

The following Wall Street analysts have issued reports on Salarius Pharmaceuticals in the last year: Benchmark Co., LADENBURG THALM/SH SH, and Zacks Investment Research.
View the latest analyst ratings for SLRX.

What is the current price target for Salarius Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Salarius Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 290.6%. Benchmark Co. has the highest price target set, predicting SLRX will reach $5.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $5.00 for Salarius Pharmaceuticals in the next year.
View the latest price targets for SLRX.

What is the current consensus analyst rating for Salarius Pharmaceuticals?

Salarius Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLRX will outperform the market and that investors should add to their positions of Salarius Pharmaceuticals.
View the latest ratings for SLRX.

What other companies compete with Salarius Pharmaceuticals?

How do I contact Salarius Pharmaceuticals' investor relations team?

Salarius Pharmaceuticals' physical mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The company's listed phone number is 832-834-6992 and its investor relations email address is [email protected] The official website for Salarius Pharmaceuticals is www.salariuspharma.com.